Mechanistic Characterization of Azetukalner: KV7 Binding, Enhanced Channel Opening, and Rational Polytherapy Potential in Epilepsy | Xenon Pharmaceuticals Inc.

Mechanistic Characterization of Azetukalner: KV7 Binding, Enhanced Channel Opening, and Rational Polytherapy Potential in Epilepsy

September 8, 2026

Mechanistic Characterization of Azetukalner: KV7 Binding, Enhanced Channel Opening, and Rational Polytherapy Potential in Epilepsy 2.8 MB

Tags

Azetukalner in Epilepsy

Congress: European Epilepsy Congress (September 6, 2026)
Authors: Sankar R, et al.

Investor inquiries

Tucker Kelly
Chief Financial Officer
investors@xenon-pharma.com

Request Information

Email alerts

Sign up here to receive email alerts from Xenon Pharmaceuticals